China Pharma Narrows Loss Amidst Revenue Dip, Going Concern Doubts Linger

TL;DR

**CPHI is bleeding cash and facing an existential crisis; steer clear unless you're a high-risk speculator.**

AI Summary

CHINA PHARMA HOLDINGS, INC. (CPHI) reported a net loss of $1.31 million for the six months ended June 30, 2025, a significant improvement from the $2.39 million net loss in the same period of 2024. Revenue decreased to $2.16 million for the first six months of 2025, down from $2.29 million in 2024. The company experienced a gross loss of $223,071, an improvement from the $1.31 million gross loss in the prior year. Operating expenses increased to $1.19 million from $1.00 million, primarily driven by a rise in general and administrative expenses to $948,016 from $580,326. Research and development expenses decreased substantially to $50,539 from $195,785. The company received a research and development subsidy of $150,690 in 2025, which was not present in 2024. As of June 30, 2025, CPHI had cash and cash equivalents of $625,032 and an accumulated deficit of $45.34 million, with current liabilities exceeding current assets by $2.55 million, raising substantial doubt about its ability to continue as a going concern.

Why It Matters

CPHI's continued net losses and significant accumulated deficit of $45.34 million, coupled with current liabilities exceeding current assets by $2.55 million, signal severe financial distress for investors. The 'going concern' warning directly impacts investor confidence and could lead to further stock price volatility and delisting risks from NYSE American. For employees, this raises job security concerns and potential operational restructuring. Customers might face uncertainty regarding product availability and long-term support, while the broader market could see CPHI as a cautionary tale for small-cap pharmaceutical companies operating in challenging regulatory and economic environments like the PRC, especially given competitive pressures in the pharmaceutical sector.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about its ability to continue as a going concern' due to an accumulated deficit of $45.34 million and current liabilities exceeding current assets by $2.55 million as of June 30, 2025. Despite cash inflows from operating activities of $0.23 million, the company anticipates continued operating losses, indicating a high probability of financial instability.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in CPHI due to the explicit 'going concern' warning and persistent financial instability. New investors should avoid CPHI until the company demonstrates a clear path to profitability and resolves its liquidity issues, as the risk of total capital loss is significant.

Financial Highlights

debt To Equity

1.13

revenue

$2.16M

operating Margin

N/A

total Assets

$13.77M

total Debt

$7.30M

net Income

-$1.31M

eps

N/A

gross Margin

-10.3%

cash Position

$625,032

revenue Growth

-5.7%

Revenue Breakdown

Key Numbers

• $1.31M — Net Loss (for six months ended June 30, 2025, improved from $2.39M in 2024)
• $2.16M — Revenue (for six months ended June 30, 2025, decreased from $2.29M in 2024)
• $45.34M — Accumulated Deficit (as of June 30, 2025, indicating significant historical losses)
• $2.55M — Current Liabilities Exceeding Current Assets (as of June 30, 2025, highlighting liquidity issues)
• $625,032 — Cash and Cash Equivalents (as of June 30, 2025, a minimal cash position)
• $150,690 — Research and Development Subsidy (received in Q2 2025, contributing to other income)
• $948,016 — General and Administrative Expenses (for six months ended June 30, 2025, increased from $580,326 in 2024)
• $50,539 — Research and Development Expenses (for six months ended June 30, 2025, decreased from $195,785 in 2024)
• $0.24M — Advances from Ms. Li (additional funds provided by CEO in Q2 2025 for working capital)
• 3,262,002 — Shares Outstanding (as of August 7, 2025, after a 1-for-10 reverse stock split)

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — registrant
• Onny Investment Limited (company) — wholly-owned subsidiary
• Hainan Helpson Medical & Biotechnology Co., Ltd (company) — wholly-owned subsidiary
• Ms. Li (person) — Chairperson, CEO, and Interim CFO
• National Medical Products Administration (regulator) — approves pharmaceutical products in PRC
• NYSE American (regulator) — exchange where common stock is registered
• Securities and Exchange Commission (regulator) — filing authority
• $1.31 million (dollar_amount) — net loss for six months ended June 30, 2025
• $45.34 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $2.5 million (dollar_amount) — current liabilities exceeding current assets as of June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: As of June 30, 2025, CPHI had current liabilities exceeding current assets by $2.55 million and an accumulated deficit of $45.34 million. This, coupled with a minimal cash position of $625,032, raises substantial doubt about the company's ability to continue as a going concern.
• Persistent Operating Losses [high — financial]: The company reported a net loss of $1.31 million for the six months ended June 30, 2025, despite an improvement from the prior year's loss of $2.39 million. The gross loss also improved to $223,071 from $1.31 million, but the company continues to operate at a loss.
• Increasing General and Administrative Expenses [medium — operational]: General and administrative expenses increased significantly to $948,016 for the first six months of 2025, up from $580,326 in the same period of 2024. This increase in overhead costs, despite declining revenue, puts pressure on profitability.
• Declining Cash and Inventories [medium — financial]: Cash and cash equivalents stood at $625,032 as of June 30, 2025, a slight decrease from $626,879 at the end of 2024. Inventories also decreased substantially from $2.27M to $1.68M, potentially indicating reduced production or sales activity.
• High Accumulated Deficit [high — financial]: The company's accumulated deficit reached $45.34 million as of June 30, 2025. This substantial historical loss indicates a long-term struggle to achieve profitability.
• Reliance on Related Party Borrowings [medium — financial]: Borrowings from related parties amounted to $1,407,607 as of June 30, 2025, an increase from $1,144,985 at the end of 2024. This highlights a reliance on internal or affiliated funding sources.

Industry Context

China Pharma Holdings operates in the pharmaceutical sector, a highly competitive and regulated industry. The market is characterized by intense R&D efforts, patent cliffs, and evolving healthcare policies. Companies often face challenges in drug development, market access, and pricing pressures. The industry is also seeing a trend towards specialized therapeutics and increased focus on generic drugs.

Regulatory Implications

As a pharmaceutical company, CPHI is subject to stringent regulations from health authorities regarding drug approval, manufacturing, marketing, and safety. Non-compliance can lead to significant fines, product recalls, and reputational damage. Changes in healthcare policies or pricing regulations in its operating markets could also materially impact its financial performance.

What Investors Should Do

1. Monitor cash burn rate and liquidity closely given the ongoing working capital deficit and minimal cash reserves.
2. Evaluate the sustainability of the improved gross loss and net loss figures, considering the revenue decline and rising G&A expenses.
3. Assess the impact of the recent reverse stock split on share price performance and market perception.
4. Investigate the long-term viability of the company's product pipeline and R&D strategy, especially given the reduced R&D spending.
5. Understand the terms and conditions of related party borrowings and their potential implications.

Key Dates

• 2025-06-30: Six Months Ended — Reporting period for the 10-Q, showing a reduced net loss but also declining revenue and a worsening current liability position.
• 2025-06-30: Balance Sheet Date — Indicates current assets of $2.70M and current liabilities of $5.25M, resulting in a working capital deficit of $2.55M.
• 2025-06-30: Cash and Cash Equivalents — Reported at $625,032, a minimal amount that contributes to going concern doubts.
• 2025-06-30: Accumulated Deficit — Reached $45.34 million, underscoring significant historical unprofitability.
• 2025-08-07: Shares Outstanding Date — Reported 3,262,002 shares outstanding after a 1-for-10 reverse stock split, indicating a recent attempt to adjust share structure.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or additional paid-in capital. (CPHI has a substantial accumulated deficit of $45.34 million, indicating a long history of unprofitability.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. (The company's financial condition raises substantial doubt about its ability to continue as a going concern.)

Current Liabilities

Obligations that are expected to be settled within one year or the operating cycle, whichever is longer. (CPHI's current liabilities ($5.25M) exceed its current assets ($2.70M), creating a working capital deficit.)

Gross Loss

Occurs when the cost of goods sold exceeds the revenue generated from sales. (CPHI reported a gross loss of $223,071, an improvement from the prior year but still indicating that production costs are higher than sales revenue.)

Reverse Stock Split

A corporate action to reduce the number of outstanding shares of stock, typically to increase the stock's market price. (CPHI recently underwent a 1-for-10 reverse stock split, affecting its share count and potentially its stock price perception.)

Research and Development Subsidy

Financial assistance provided by a government or other entity to support research and development activities. (CPHI received a $150,690 subsidy in 2025, which positively impacted its other income.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, CPHI reported a net loss of $1.31 million, an improvement from $2.39 million in the prior year. Revenue, however, declined by 5.7% to $2.16 million. While the gross loss significantly improved from $1.31 million to $223,071, operating expenses rose due to a substantial increase in general and administrative costs. The company's liquidity position worsened, with current liabilities now exceeding current assets by $2.55 million, and the accumulated deficit grew to $45.34 million.

Key Financial Figures

• $0.01 — were 3,262,002 shares of common stock, $0.01 par value per share, issued and outstan

Filing Documents

• ea0252218-10q_china.htm (10-Q) — 552KB
• ea025221801ex31-1_china.htm (EX-31.1) — 10KB
• ea025221801ex31-2_china.htm (EX-31.2) — 10KB
• ea025221801ex32-1_china.htm (EX-32.1) — 5KB
• 0001213900-25-076642.txt ( ) — 4051KB
• cphi-20250630.xsd (EX-101.SCH) — 38KB
• cphi-20250630_cal.xml (EX-101.CAL) — 40KB
• cphi-20250630_def.xml (EX-101.DEF) — 183KB
• cphi-20250630_lab.xml (EX-101.LAB) — 336KB
• cphi-20250630_pre.xml (EX-101.PRE) — 195KB
• ea0252218-10q_china_htm.xml (XML) — 367KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 23 Item 4.

Controls and Procedures

Controls and Procedures 23

OTHER INFORMATION

PART II OTHER INFORMATION 24 Item 6. Exhibits 26 i

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 (Unaudited) 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 5 Notes to Condensed Consolidated Financial Statements (Unaudited) 6 1 CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, December 31, 2025 2024 ASSETS Current Assets: Cash and cash equivalents $ 625,032 $ 626,879 Banker's acceptances - 18,642 Trade accounts receivable, less allowance for credit losses of $ 13,644,006 and $ 13,587,182 , respectively 268,793 232,140 Other receivables, less allowance for credit losses of $ 29,014 and $ 28,447 , respectively 48,361 30,286 Advances to suppliers 4,967 14,960 Inventories 1,678,769 2,266,154 Prepaid expenses 74,869 81,328 Total Current Assets 2,700,791 3,270,389 Property, plant and equipment, net 4,625,907 4,883,401 Right-of-use assets - 38,298 Intangible assets, net 6,439,862 6,695,436 TOTAL ASSETS $ 13,766,560 $ 14,887,524 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Trade accounts payable $ 530,729 $ 225,106 Accrued expenses 191,293 247,159 Other payables 2,344,882 2,182,982 Contract liabilities 77,683 162,208 Borrowings from related parties 1,407,607 1,144,985 Lease liabilities - 39,323 Current portion of lines of credit 698,461 1,015,525 Total Current Liabilities 5,250,655 5,017,288 Non-current Liabilities: Lines of credit, net of current portion 1,319,915 1,391,130 Deferred tax liability 734,246 731,202

View Full Filing

View this 10-Q filing on SEC EDGAR